Potentially dilutive shares of common stock were excluded
from the computation of diluted shares outstanding for the years ended December 31, 2024 and 2023 as they would have an anti-dilutive
impact on the Company’s net losses in that period and consisted of the following:
SCHEDULE
OF POTENTIALLY DILUTIVE SHARES EXCLUDED FROM COMPUTING OF DILUTED SHARES OUTSTANDING
| | |
December 31, 2024 | | |
December 31, 2023 | |
| Stock warrants | |
| 946,171,489 | | |
| 948,452,679 | |
| Stock options | |
| - | | |
| 80,000 | |
| Series E convertible preferred stock | |
| 95,238,667 | | |
| 95,238,667 | |
| Series G convertible preferred stock | |
| 2,032,500,000 | | |
| 2,377,500,000 | |
| Series H convertible preferred stock | |
| 323,740,000 | | |
| 323,740,000 | |
| Antidilutive securities
excluded from computation of earnings per share | |
| 3,397,650,156 | | |
| 3,745,011,346 | |
|